Cerenome (PSTV) Short term Debt (2010 - 2026)

Plus Therapeutics (PSTV) posted quarterly Short term Debt of $667000.0 for Q1 2026, down 11.07% quarter-over-quarter from $750000.0 in Q4 2025.

Cerenome (PSTV) Short term Debt (2010 - 2026) Analysis & Trends

Plus Therapeutics (PSTV) has reported Short term Debt for 17 consecutive years, with $667000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Short term Debt changed N/A year-over-year to $667000.0; the TTM figure through Mar 2026 stood at $667000.0 (changed N/A YoY), while the FY2025 annual figure was $750000.0, down 77.22% from the prior year.
Short term Debt eased to $667000.0 in Q1 2026 per PSTV's latest filing, from $750000.0 in the prior quarter.
Across five years, Short term Debt topped out at $5.1 million in Q1 2023 and bottomed at $667000.0 in Q1 2026.
Historically, Short term Debt has averaged $2.8 million across 5 years, with a median of $3.3 million in 2024.
Annual changes were most pronounced in 2023 — Short term Debt jumped 214.49% — and 2025, when it slumped 77.22%.
Plus Therapeutics' Short term Debt stood at $1.6 million in 2022, then surged by 147.26% to $4.0 million in 2023, then fell by 17.2% to $3.3 million in 2024, then plunged by 77.22% to $750000.0 in 2025, then dropped by 11.07% to $667000.0 in 2026.
Business Quant data shows PSTV's Short term Debt at $667000.0 in Q1 2026, $750000.0 in Q4 2025, and $3.3 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.25 Bn	131.40 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.04 Bn	78.05 Bn	3.93 Bn
3	Argenx Se	65.43 Bn	60.25 Bn	1.37 Bn
4	Moderna	58.26 Bn	53.13 Bn	52.00 Mn
5	BeOne Medicines	42.10 Bn	37.00 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.61 Bn	28.31 Bn	992.69 Mn
7	BioNTech SE	28.03 Bn	9.63 Bn	668.28 Mn
8	Insmed	27.49 Bn	26.33 Bn	358.27 Mn
9	Royalty Pharma	27.33 Bn	26.49 Bn	-
10	Cerenome	28.07 Mn	19.48 Mn	-

Download Data